New Case Series Investigates the Combined Use of Masimo SedLine® Brain Function Monitoring and O3® Regional Oximetry During Cardiac Surgery

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MH

Go back to New Case Series Investigates the Combined Use of Masimo SedLine® Brain Function Monitoring and O3® Regional Oximetry During Cardiac Surgery

Masimo Corp. (MASI) PT Raised to $148 at Needham & Company

February 27, 2019 8:27 AM EST

Needham & Company analyst Michael Matson raised the price target on Masimo Corp. (NASDAQ: MASI) to $148.00 (from $139.00) while maintaining a Buy rating following the company's 4Q. Revenue was $223M vs. consensus of $219M and Product non-GAAP EPS was $0.81 vs. consensus of $0.73.

Matson expects... More